D V Havlir

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients
    D V Havlir
    Department of Medicine, University of California, San Diego 92103, USA
    J Virol 70:7894-9. 1996
  2. pmc Structured intermittent treatment for HIV disease: Necessary concession or premature compromise?
    Diane V Havlir
    Division of Infectious Diseases, University of California, 150 West Washington Street, Suite 100, San Diego, CA 92103, USA
    Proc Natl Acad Sci U S A 99:4-6. 2002
  3. ncbi request reprint Prevalence and predictive value of intermittent viremia with combination hiv therapy
    D V Havlir
    University of California, San Diego, 150 W Washington, Suite 100, San Diego, CA 92103, USA
    JAMA 286:171-9. 2001
  4. ncbi request reprint Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects
    D V Havlir
    Department of Medicine, University of California, San Diego, UCSD Treatment Center, San Diego, CA 92103, USA
    J Infect Dis 182:1658-63. 2000
  5. ncbi request reprint In vivo antagonism with zidovudine plus stavudine combination therapy
    D V Havlir
    1University of California, San Diego, 2San Diego VA Medical Center, San Diego, California, USA
    J Infect Dis 182:321-5. 2000
  6. ncbi request reprint Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
    D V Havlir
    University of California, San Diego 92103, USA
    JAMA 283:229-34. 2000
  7. ncbi request reprint Human immunodeficiency virus replication in AIDS patients with Mycobacterium avium complex bacteremia: a case control study. California Collaborative Treatment Group
    D V Havlir
    University of California, San Diego, USA
    J Infect Dis 177:595-9. 1998
  8. ncbi request reprint Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression
    D V Havlir
    University of California at San Diego and the San Diego Veterans Affairs Healthcare System, San Diego, California 92103, USA
    AIDS 15:1379-88. 2001
  9. pmc Serum interleukin-6 (IL-6), IL-10, tumor necrosis factor (TNF) alpha, soluble type II TNF receptor, and transforming growth factor beta levels in human immunodeficiency virus type 1-infected individuals with Mycobacterium avium complex disease
    D V Havlir
    Department of Medicine, University of California, San Diego, California 92103, USA
    J Clin Microbiol 39:298-303. 2001
  10. pmc Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure
    J K Wong
    Department of Medicine, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
    Proc Natl Acad Sci U S A 94:12574-9. 1997

Detail Information

Publications44

  1. pmc Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients
    D V Havlir
    Department of Medicine, University of California, San Diego 92103, USA
    J Virol 70:7894-9. 1996
    ..In two subjects, the calculated prevalence of the 181 mutant virus prior to treatment was 7 and 133 per 10,000 copies of plasma HIV RNA...
  2. pmc Structured intermittent treatment for HIV disease: Necessary concession or premature compromise?
    Diane V Havlir
    Division of Infectious Diseases, University of California, 150 West Washington Street, Suite 100, San Diego, CA 92103, USA
    Proc Natl Acad Sci U S A 99:4-6. 2002
  3. ncbi request reprint Prevalence and predictive value of intermittent viremia with combination hiv therapy
    D V Havlir
    University of California, San Diego, 150 W Washington, Suite 100, San Diego, CA 92103, USA
    JAMA 286:171-9. 2001
    ....
  4. ncbi request reprint Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects
    D V Havlir
    Department of Medicine, University of California, San Diego, UCSD Treatment Center, San Diego, CA 92103, USA
    J Infect Dis 182:1658-63. 2000
    ..avium occurred in 76% of DMAC subjects receiving HAART. CD4 and CD8 but not gammadelta T cells expanded in response to M. avium. CMI to M. avium reconstitutes rapidly after HAART and appears sustained even with partial viral suppression...
  5. ncbi request reprint In vivo antagonism with zidovudine plus stavudine combination therapy
    D V Havlir
    1University of California, San Diego, 2San Diego VA Medical Center, San Diego, California, USA
    J Infect Dis 182:321-5. 2000
    ..Analysis of these data suggests that zidovudine and d4T should not be prescribed in combination and that ddI provides greater antiviral activity than d4T in zidovudine-treated patients...
  6. ncbi request reprint Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
    D V Havlir
    University of California, San Diego 92103, USA
    JAMA 283:229-34. 2000
    ....
  7. ncbi request reprint Human immunodeficiency virus replication in AIDS patients with Mycobacterium avium complex bacteremia: a case control study. California Collaborative Treatment Group
    D V Havlir
    University of California, San Diego, USA
    J Infect Dis 177:595-9. 1998
    ..01). In AIDS patients, the onset of MAC bacteremia is associated with a modest but significant increase in serum HIV RNA levels. Increased HIV replication may contribute to the higher mortality associated with MAC bacteremia...
  8. ncbi request reprint Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression
    D V Havlir
    University of California at San Diego and the San Diego Veterans Affairs Healthcare System, San Diego, California 92103, USA
    AIDS 15:1379-88. 2001
    ..CONCLUSIONS: Switching to IDV + ddI + d4T + HU in patients treated with IDV + ZDV + 3TC was associated with a worse outcome, principally because of drug toxicity...
  9. pmc Serum interleukin-6 (IL-6), IL-10, tumor necrosis factor (TNF) alpha, soluble type II TNF receptor, and transforming growth factor beta levels in human immunodeficiency virus type 1-infected individuals with Mycobacterium avium complex disease
    D V Havlir
    Department of Medicine, University of California, San Diego, California 92103, USA
    J Clin Microbiol 39:298-303. 2001
    ..Thus, antibiotic treatment for MAC results in decreased levels of IL-6 and TNF-alpha in serum in HIV-1-infected persons who are not on HAART...
  10. pmc Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure
    J K Wong
    Department of Medicine, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
    Proc Natl Acad Sci U S A 94:12574-9. 1997
    ..Conversely, the persistence of even modest levels of plasma virus after 1 year of treatment reflects ongoing viral replication, the emergence of drug resistance, and the maintenance of high burdens of virus in the lymph nodes...
  11. pmc Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata
    G Chamie
    HIV AIDS Division, San Francisco General Hospital, University of California, San Francisco, California 94110, USA
    Int J Tuberc Lung Dis 14:1295-302. 2010
    ..The human immunodeficiency virus (HIV) alters the presentation of pulmonary tuberculosis (PTB), but it remains unclear whether alterations occur at a CD4 cell threshold or throughout HIV infection...
  12. doi request reprint Household ventilation and tuberculosis transmission in Kampala, Uganda
    G Chamie
    Division of HIV AIDS, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California 94143 0874, USA
    Int J Tuberc Lung Dis 17:764-70. 2013
    ..To test the feasibility of measuring household ventilation and evaluate whether ventilation is associated with tuberculosis (TB) in household contacts in Kampala, Uganda...
  13. pmc Viral dynamics of acute HIV-1 infection
    S J Little
    Department of Medicine, University of California San Diego, San Diego, California 92103, USA
    J Exp Med 190:841-50. 1999
    ..These measurements provide a basis for comparison of vaccine and other strategies and support the validity of the simian immunodeficiency virus macaque model of acute HIV infection...
  14. pmc Elevated HIV seroprevalence and risk behavior among Ugandan TB suspects: implications for HIV testing and prevention
    P Srikantiah
    Division of HIV AIDS, San Francisco General Hospital, University of California, San Francisco 94110, USA
    Int J Tuberc Lung Dis 11:168-74. 2007
    ..Opportunities to diagnose HIV may be missed by limiting HIV testing to only persons diagnosed with TB. Among TB suspects in Uganda, we determined HIV prevalence, risk behaviors, and willingness to refer family for VCT...
  15. ncbi request reprint A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086
    Constance A Benson
    University of California, San Diego School of Medicine, San Diego, CA 92103, USA
    J Infect Dis 194:1309-18. 2006
    ..The role of structured treatment interruption (STI) before optimized antiretroviral therapy (ART) in patients with drug-resistant human immunodeficiency virus type 1 (HIV-1) is uncertain...
  16. ncbi request reprint Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials
    Francois Xavier Blanc
    Agence Nationale de Recherches sur le Sida et les Hepatites Virales, Paris, France
    J Infect Dis 196:S46-51. 2007
    ..Here, we present an overview of these ongoing or planned clinical studies, which are supported by international agencies...
  17. ncbi request reprint High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    HIV Clin Trials 8:193-204. 2007
    ..To investigate the efficacy and safety of high-dose lopinavir/ritonavir (LPV/r) therapy in multiple protease inhibitor, non-nucleoside reverse transcriptase inhibitor (NNRTI)-experienced subjects...
  18. ncbi request reprint Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda
    Padmini Srikantiah
    HIV AIDS Division, San Francisco General Hospital, University of California, San Francisco, California, USA
    AIDS 21:1972-4. 2007
    ..No cases of hypersensitivity or immune reconstitution syndrome were observed. These data support the continuing evaluation of nucleoside-based antiretroviral regimens as an alternative treatment for this population...
  19. pmc Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy
    C Bradley Hare
    Dept of Medicine, University of California, San Francisco, CA 94110, USA
    Clin Infect Dis 47:421-4. 2008
    ..Mutations remained detectable for at least 48 weeks in some subjects...
  20. doi request reprint HIV integrase inhibitors--out of the pipeline and into the clinic
    Diane V Havlir
    N Engl J Med 359:416-8. 2008
  21. ncbi request reprint Antiretroviral therapy and TB
    Soumya Swaminathan
    Division of HIV AIDS, Tuberculosis Research Centre, Chennai, India
    Trop Doct 36:73-9. 2006
    ..Despite the complexities presented by co-infection, many programmes have integrated care and are successfully treating patients with both HIV and TB...
  22. ncbi request reprint Strategic approaches to antiretroviral treatment
    Diane V Havlir
    University of California San Francisco, San Francisco, CA, USA
    Top HIV Med 11:145-9. 2003
    ..This article summarizes a presentation given by Diane V. Havlir, MD, at the March 2003 International AIDS Society-USA course in Los Angeles...
  23. ncbi request reprint Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression
    Victor Appay
    Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    AIDS 16:161-70. 2002
    ..It leads to significant reductions of plasma viremia, often to undetectable levels, but it can also be linked with the reduction and disappearance of detectable HIV-specific CD8 T-cell responses...
  24. ncbi request reprint Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapy
    Kara K Bennett
    SDAC, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Acquir Immune Defic Syndr 31:20-6. 2002
    ..01) had higher increases in phase I changes. Phase II CD4 cell counts did not depend solely on baseline HIV-1 RNA levels and CD4 cell counts but on their interaction (p =.0001) as well as on achieving virologic suppression (p =.0009)...
  25. ncbi request reprint Responding to organ failure in HIV-infected patients
    Michelle E Roland
    AIDS Division, Positive Health Program, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, USA
    N Engl J Med 348:2279-81. 2003
  26. ncbi request reprint Nontuberculous mycobacteria in the HIV infected patient
    Denis Jones
    School of Medicine, University of California, Mail Code 8208, 150 W Washington Street, 100, San Diego, CA 92103, USA
    Clin Chest Med 23:665-74. 2002
    ..Clinicians treating HIV-infected patients must remain familiar with the diagnosis and treatment of these diseases and implement prevention strategies when indicated...
  27. ncbi request reprint Complications of HIV disease and therapy
    Judith S Currier
    University of California Los Angeles, Los Angeles, CA, USA
    Top HIV Med 15:40-7. 2007
    ..As the field of clinical research in HIV continues to mature, we are repeatedly surprised by the findings from well-designed studies...
  28. ncbi request reprint Complications of HIV infection and antiretroviral therapy
    Diane V Havlir
    University of California San Francisco, San Francisco, CA, USA
    Top HIV Med 11:86-91. 2003
  29. pmc HIV RNA suppression among HIV-infected Ugandan children with measles
    Theodore D Ruel
    J Acquir Immune Defic Syndr 48:225-7. 2008
  30. doi request reprint Opportunities and challenges for HIV care in overlapping HIV and TB epidemics
    Diane V Havlir
    Department of Medicine, University of California, San Francisco, USA
    JAMA 300:423-30. 2008
    ....
  31. ncbi request reprint Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections
    Victor Appay
    MRC Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Med 8:379-85. 2002
    ..These findings challenge the current definitions of memory and effector subsets in humans, and suggest that ascribing effector and memory functions to subsets with different differentiation phenotypes is no longer appropriate...
  32. ncbi request reprint The case for earlier treatment of HIV infection
    Scott D Holmberg
    Division of HIV AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Clin Infect Dis 39:1699-704. 2004
    ..Given these accumulating data, we believe reconsideration of the "when-to-start" question is timely and justified...
  33. pmc Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years
    Diane V Havlir
    Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California 94110, USA
    J Virol 77:11212-9. 2003
    ....
  34. pmc Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals
    Annie F Luetkemeyer
    HIV AIDS Division, San Francisco General Hospital, University of California at San Fracisco, San Francisco, Box 0874, Building 80, 995 Potrero Avenue, San Francisco, CA 94110, USA
    Am J Respir Crit Care Med 175:737-42. 2007
    ..Although interferon (IFN)-gamma release assays are approved for the diagnosis of latent tuberculosis infection (LTBI), limited data exist regarding their performance in HIV infection...
  35. ncbi request reprint Atazanavir: new option for treatment of HIV infection
    Diane V Havlir
    San Francisco General Hospital, University of California, San Francisco, California, USA
    Clin Infect Dis 38:1599-604. 2004
    ..Similar to other protease inhibitors, careful attention must be paid to drug interactions when administering atazanavir with concomitant medications...
  36. ncbi request reprint Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine
    Diane V Havlir
    Department of Medicine, San Francisco General Hospital, University of California at San Francisco, San Francisco, California, USA
    J Infect Dis 191:1164-8. 2005
    ..05). However, a level of residual viremia <50 copies/mL was not associated with CD4 cell count changes or risk of virologic rebound through 72 weeks of follow-up...
  37. ncbi request reprint Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1
    Matthew C Strain
    Department of Physics, University of California at San Diego, La Jolla, California, USA
    J Infect Dis 191:1410-8. 2005
    ..1 IUPM; P<.0005). These results suggest that treatment <6 months after seroconversion may facilitate long-term control of cellular reservoirs that maintain HIV-1 infection during treatment...
  38. ncbi request reprint Complications of HIV disease and antiretroviral therapy
    Judith S Currier
    University of California Los Angeles, Los Angeles, CA, USA
    Top HIV Med 13:16-23. 2005
    ....
  39. ncbi request reprint Patents versus patients? Antiretroviral therapy in India
    Diane V Havlir
    University of California, San Francisco, USA
    N Engl J Med 353:749-51. 2005
  40. ncbi request reprint Rapid increase in tuberculosis incidence soon after infection with HIV--a new twist in the twin epidemics
    Padmini Srikantiah
    J Infect Dis 191:147-9. 2005
  41. ncbi request reprint Complications of HIV disease and antiretroviral therapy
    Diane V Havlir
    University of California San Francisco, CA, USA
    Top HIV Med 14:27-35. 2006
    ..This review will summarize information on complications of antiretroviral therapy in resource-limited settings, hepatitis C virus, tuberculosis, and discussion of metabolic, cardiovascular, and renal complications...
  42. ncbi request reprint Intensive care of patients with HIV infection
    Laurence Huang
    HIV AIDS Division, San Francisco General Hospital, University of California San Francisco, San Francisco, USA
    N Engl J Med 355:173-81. 2006
  43. ncbi request reprint Complications of HIV disease and antiretroviral therapy. Highlights of the 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco, California, USA
    Judith S Currier
    University of California Los Angeles, Los Angeles, CA, USA
    Top HIV Med 12:31-45. 2004
    ..This article summarizes these presentations...
  44. ncbi request reprint Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170
    Daniel J Skiest
    Baystate Medical Center, Springfield, MA 01106, USA
    J Infect Dis 195:1426-36. 2007
    ..We sought to determine the safety of treatment interruption (TI) and to identify parameters that would define patients with human immunodeficiency virus (HIV) for whom TI is safer...